Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in PMCB held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 196K | $130K | +58.0% | 1.823% | 0.00% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 57K | $38K | -39.9% | 0.526% | 0.00% |
| 3 | XTX Topco Ltd | 52K | $35K | +114.2% | 0.488% | 0.00% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 51K | $34K | β | 0.479% | 0.00% |
| 5 | NORTHERN TRUST CORP | 36K | $24K | 0.0% | 0.332% | 0.00% |
| 6 | Schonfeld Strategic Advisors LLC | 27K | $18K | +3.2% | 0.252% | 0.00% |
| 7 | VANGUARD FIDUCIARY TRUST CO | 23K | $16K | β | 0.218% | 0.00% |
| 8 | EQUITEC PROPRIETARY MARKETS, LLC | 22K | $15K | 0.0% | 0.207% | 0.01% |
| 9 | SIMPLEX TRADING, LLC | 20K | $13K | -22.8% | 0.186% | 0.00% |
| 10 | TWO SIGMA SECURITIES, LLC | 16K | $11K | -33.4% | 0.152% | 0.00% |
| 11 | JANE STREET GROUP, LLC | 12K | $8K | +1.2% | 0.107% | 0.00% |
| 12 | Ground Swell Capital, LLC | 12K | $8K | β | 0.107% | 0.02% |
| 13 | COMMONWEALTH EQUITY SERVICES, LLC | 10K | $7K | β | 0.096% | 0.00% |
| 14 | Tower Research Capital LLC (TRC) | 5K | $3K | -0.2% | 0.045% | 0.00% |
| 15 | UBS Group AG | 5K | $3K | +64.6% | 0.042% | 0.00% |
| 16 | GROUP ONE TRADING, L.P. | 2K | $1K | β | 0.017% | 0.00% |
| 17 | ADVISOR GROUP HOLDINGS, INC. | 302 | $200 | -0.3% | 0.003% | 0.00% |
| 18 | Virtu Financial LLC | 38K | $25 | β | 0.350% | 0.00% |
| 19 | HRT FINANCIAL LP | 25K | $16 | -86.5% | 0.231% | 0.00% |
| 20 | Sachetta, LLC | 14 | $10 | 0.0% | 0.000% | 0.00% |
| 21 | Western Wealth Management, LLC | 13 | $9 | β | 0.000% | 0.00% |
| 22 | BFSG, LLC | 5 | $4 | 0.0% | 0.000% | 0.00% |
| 23 | FINANCIAL CONSULATE, INC | 2 | $2 | 0.0% | 0.000% | 0.00% |
| 24 | SBI Securities Co., Ltd. | 3 | $2 | β | 0.000% | 0.00% |
| 25 | HARBOUR INVESTMENTS, INC. | 3 | $2 | β | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in PMCB β a direct measure of their conviction.
Filings activity in PMCB during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 35 | +21% | 4.44% | 0.62 pp | $0M | 12% |
| Q4 2025 | 29 | +26% | 5.06% | +0.11 pp | $0M | +2.2% |
| Q3 2025 | 23 | 12% | 4.95% | 2.79 pp | $0M | 36% |
| Q2 2025 | 26 | 3.7% | 7.74% | 0.95 pp | $1M | 11% |
| Q1 2025 | 27 | +13% | 8.69% | 2.75 pp | $1M | 24% |
| Q4 2024 | 24 | 20% | 11.44% | 7.80 pp | $1M | 41% |
| Q3 2024 | 30 | 9.1% | 19.24% | 5.64 pp | $2M | 23% |
| Q2 2024 | 33 | β | 24.88% | β | $2M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying PMCB stock.
Based on Q1 2026 13F filings, institutional ownership of PharmaCyte Biotech, Inc. stands at 4.4%, held across 35 reporting institutions.
GEODE CAPITAL MANAGEMENT, LLC is the largest reported institutional holder of PMCB, with approximately 195,660 shares worth $0.00B as of Q1 2026.
Yes β 3 widely-followed marquee investors appear among the top 25 institutional holders of PMCB, including RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA SECURITIES, LLC, JANE STREET GROUP, LLC.
Our composite Smart Money Score for PMCB is 61 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
12 institutions opened new positions in PMCB during Q1 2026, while 6 fully exited. 3 added to existing positions and 12 trimmed.
PMCB institutional ownership fell by 0.62 percentage points quarter-over-quarter, with a net change of +6 holders.
The top 10 institutions account for 91.8% of all reported 13F value in PMCB, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
PharmaCyte Biotech, Inc. (PMCB) Institutional Ownership